Loading...
Pre- and postoperative chemotherapy is a care standard for operable gastric cancer. For cancers of the esophagus and gastroesophageal junction, combined preoperative chemotherapy and radiotherapy is preferred over chemotherapy alone to enhance rates of curative resection and reduce local disease recurrence.
Investigators now report results of an industry-supported, multicenter, open-label, randomized, phase III trial to test the efficacy and safety of adding bevacizumab to perioperative chemotherapy in operable gastroesophageal cancer. Patients received three cycles of epirubicin, cisplatin, and capecitabine (ECX) followed by surgery followed by three cycles of postoperative ECX with or without bevacizumab (7.5 mg/kg once every 3 weeks). Of …